상세 보기
ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
- Ghia, Paolo;
- Pluta, Andrzej;
- Wach, Malgorzata;
- Lysak, Daniel;
- Kozak, Tomas;
- ... Lee, Jae Hoon;
- 외 14명
Citations
WEB OF SCIENCE
0- 제목
- ASCEND Phase 3 study of acalabrutinib versus investigator's choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
- 저자
- Ghia, Paolo; Pluta, Andrzej; Wach, Malgorzata; Lysak, Daniel; Kozak, Tomas; Simkovic, Martin; Kaplan, Polina; Kraychok, Iryna; Illes, Arpad; de la Serna, Javier; Dolan, Sean; Campbell, Philip; Musuraca, Gerardo; Jacob, Abe; Avery, E. J.; Lee, Jae Hoon; Liang, Wei; Patel, Priti; Quah, Cheng; Jurczak, Wojciech
- 발행일
- 2020-03
- 유형
- Meeting Abstract
- 권
- 61
- 페이지
- 235 ~ 237
- 언어
- ENG
- 출판사
- TAYLOR & FRANCIS LTD
- 발행국가
- 영국
- 분량
- 3 페이지
- ISSN
- E 1029-2403
P 1042-8194